PlumX Metrics
Embed PlumX Metrics

Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets

Tumor Biology, ISSN: 1423-0380, Vol: 34, Issue: 4, Page: 2041-2051
2013
  • 318
    Citations
  • 0
    Usage
  • 185
    Captures
  • 1
    Mentions
  • 30
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    318
  • Captures
    185
  • Mentions
    1
    • References
      1
      • Wikipedia
        1
  • Social Media
    30
    • Shares, Likes & Comments
      30
      • Facebook
        30

Review Description

Biomarkers are used as tools in cancer diagnostics and in treatment stratification. In most cancers, there are increased levels of one or several members of the matrix metalloproteinases (MMPs). This is a family of proteolytic enzymes that are involved in many phases of cancer progression, including angiogenesis, invasiveness, and metastasis. It has therefore been expected that MMPs could serve as both diagnostic and prognostic markers in cancer patients, but despite a huge number of studies, it has been difficult to establish MMPs as cancer biomarkers. In the present paper, we assess some of the challenges associated with MMP research as well as putative reasons for the conflicting data on the value of these enzymes as diagnostic and prognostic markers in cancer patients. We also review the prognostic value of a number of MMPs in patients with lung, colorectal, breast, and prostate cancers. The review also discusses MMPs as potential target molecules for therapeutic agents and new strategies for development of such drugs. © 2013 International Society of Oncology and BioMarkers (ISOBM).

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know